| dc.contributor.author | Rule, Simon | |
| dc.contributor.author | Jurczak, W | |
| dc.contributor.author | Jerkeman, M | |
| dc.contributor.author | Rusconi, C | |
| dc.contributor.author | Trneny, M | |
| dc.contributor.author | Offner, F | |
| dc.contributor.author | Caballero, D | |
| dc.contributor.author | Joao, C | |
| dc.contributor.author | Witzens-Harig, M | |
| dc.contributor.author | Hess, G | |
| dc.contributor.author | Bence-Bruckler, I | |
| dc.contributor.author | Cho, S-G | |
| dc.contributor.author | Thieblemont, C | |
| dc.contributor.author | Zhou, W | |
| dc.contributor.author | Henninger, T | |
| dc.contributor.author | Goldberg, J | |
| dc.contributor.author | Vermeulen, J | |
| dc.contributor.author | Dreyling, M | |
| dc.date.accessioned | 2018-04-23T10:51:38Z | |
| dc.date.issued | 2018-02-02 | |
| dc.identifier.issn | 0887-6924 | |
| dc.identifier.issn | 1476-5551 | |
| dc.identifier.uri | http://hdl.handle.net/10026.1/11324 | |
| dc.format.extent | 1799-1803 | |
| dc.format.medium | Print-Electronic | |
| dc.language | en | |
| dc.language.iso | en | |
| dc.publisher | Springer Science and Business Media LLC | |
| dc.subject | Adenine | |
| dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
| dc.subject | Follow-Up Studies | |
| dc.subject | Humans | |
| dc.subject | International Agencies | |
| dc.subject | Lymphoma, Mantle-Cell | |
| dc.subject | Piperidines | |
| dc.subject | Prognosis | |
| dc.subject | Pyrazoles | |
| dc.subject | Pyrimidines | |
| dc.subject | Salvage Therapy | |
| dc.subject | Sirolimus | |
| dc.subject | Survival Rate | |
| dc.title | Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. | |
| dc.type | journal-article | |
| dc.type | Clinical Trial, Phase III | |
| dc.type | Comparative Study | |
| dc.type | Journal Article | |
| dc.type | Multicenter Study | |
| dc.type | Randomized Controlled Trial | |
| dc.type | Research Support, Non-U.S. Gov't | |
| plymouth.author-url | https://www.ncbi.nlm.nih.gov/pubmed/29572505 | |
| plymouth.issue | 8 | |
| plymouth.volume | 32 | |
| plymouth.publication-status | Published | |
| plymouth.journal | Leukemia | |
| dc.identifier.doi | 10.1038/s41375-018-0023-2 | |
| plymouth.organisational-group | /Plymouth | |
| plymouth.organisational-group | /Plymouth/Faculty of Health | |
| plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
| plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
| plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
| plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine | |
| plymouth.organisational-group | /Plymouth/Research Groups | |
| plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
| plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR | |
| plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CCT&PS | |
| plymouth.organisational-group | /Plymouth/Users by role | |
| plymouth.organisational-group | /Plymouth/Users by role/Academics | |
| dc.publisher.place | England | |
| dcterms.dateAccepted | 2017-12-22 | |
| dc.rights.embargodate | 2018-7-11 | |
| dc.identifier.eissn | 1476-5551 | |
| dc.rights.embargoperiod | 6 months | |
| rioxxterms.versionofrecord | 10.1038/s41375-018-0023-2 | |
| rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
| rioxxterms.licenseref.startdate | 2018-02-02 | |
| rioxxterms.type | Journal Article/Review | |
